Congress moves to set drug prices directly—bypassing negotiation.

What it does

This bill creates a federal Prescription Drug Price Regulatory Commission that will recommend 'fair prices' for all approved prescription drugs, which the Secretary of HHS will then publish and enforce. Manufacturers must sell drugs at or below these government-set prices to patients, pharmacies, hospitals, and providers, or face civil penalties of up to 10 times the overcharge amount. The bill also grants the government march-in rights to patent licenses and Defense Production Act authority if supply is inadequate.

Why we flagged it

The bill's core mechanism is direct government price-setting for all approved prescription drugs, enforced through civil penalties and private litigation. This is fundamentally a price-control regime, not a negotiation framework or transparency measure.

What the text implies

• The bill grants the President Defense Production Act authority to compel domestic drug manufacturing if foreign supply is deemed unreliable—a significant expansion of executive power over pharmaceutical production that could affect supply chains globally.
• March-in rights (Section 5) allow the Secretary to claim patent licenses if prices exceed the fair price or supply is inadequate. This effectively subordinates patent rights to price-control policy, potentially discouraging innovation investment.
• The Commission is exempt from the Administrative Procedure Act (Chapter 10, Title 5), meaning its price recommendations may not be subject to standard notice-and-comment rulemaking, reducing transparency in the price-setting process.
• Private right of action with treble damages (up to 3x actual damages or $50k per violation) creates significant litigation risk for manufacturers and may incentivize aggressive enforcement by private plaintiffs, potentially destabilizing pricing.
• The bill defines 'fair price eligible individual' as anyone in the US at time of dispensing, but does not explicitly address how uninsured or underinsured patients access these prices—implementation details could determine whether the benefit reaches the most vulnerable.

Who it affects

Ordinary Americans with prescription drug costs stand to benefit from lower, government-negotiated drug prices modeled on international reference pricing. The enforcement mechanisms (civil penalties, private right of action, state attorney general authority) create multiple accountability pathways. However, the bill's success depends entirely on the Commission's composition and the Secretary's judgment in setting prices—if prices are set too high or exemptions are granted too liberally, the bene

Who stands to gain

• patients and consumers (lower out-of-pocket drug costs)
• state governments (enforcement authority, potential cost savings in Medicaid)
• generic drug manufacturers (potential competitive advantage if branded drugs are price-capped)

Named in the bill

Prescription Drug Price Regulatory Commission, Secretary of Health and Human Services, Food and Drug Administration, Centers for Medicare & Medicaid Services, Federal Trade Commission, Veterans Health Administration, Defense Health Agency, Centers for Disease Control and Prevention, Defense Production Act of 1950, Federal Food, Drug, and Cosmetic Act, Social Security Act, comparable reference countries (Canada, France, Germany, Italy, Japan, UK)

Where it stands

• May 26, 2026 — Introduced · Congress.gov: “Introduced in House”
• May 26, 2026 — Referred to House Committee on Financial Services and House Committee on the Judiciary · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.